Probenecid is a chemosensitizer in cancer cell lines (Q39485986)

12 September 2017

title

Probenecid is a chemosensitizer in cancer cell lines (English)

1 reference

12 September 2017

1 reference

ChEBI release 2020-05-28

Denise Campos-Arroyo

1

1 reference

12 September 2017

Juan Carlos Martínez-Lazcano

series ordinal

2

1 reference

12 September 2017

Jorge Melendez-Zajgla

series ordinal

3

1 reference

12 September 2017

publication date

23 August 2011

1 reference

Cancer Chemotherapy and Pharmacology

12 September 2017

published in

1 reference

12 September 2017

volume

69

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

495-504

1 reference

Cisplatin-associated nephrotoxicity and pathological events

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Peripheral neuropathy induced by microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Paclitaxel-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

P-glycoprotein and multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Structure-activity relationships of tariquidar analogs as multidrug resistance modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Oxaliplatin activity in head and neck cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Gemcitabine activity in cervical cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Transport of the natural sweetener stevioside and its aglycone steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Both P-gp and MRP contribute to drug resistance in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Probenecid, a gout remedy, inhibits pannexin 1 channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Systematic review of systemic therapy for advanced or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Volume-sensitive outwardly rectifying chloride channels are involved in oxidative stress-induced apoptosis of mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Exogenous glutathione protects intestinal epithelial cells from oxidative injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Glutathione uptake and protection against oxidative injury in isolated kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Tumor-targeted induction of oxystress for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

The platinum (II) complex [Pt(O,O'-acac)(γ-acac)(DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1725-6

10.1007/S00280-011-1725-6

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference